Who supplies these components today
The incumbents are medtech-native thin-film houses competing on regulatory record and design partnership, not display-supply-chain peers competing on cost per square meter.
- Position
- Thin-film circuits, electroforming, electrodes and catheters. Additive thin-film lines and spaces down to 3 micrometers and vias to 25 micrometers on polyimide or alumina, for neural and biosensor arrays. Eleven global facilities with Class 7 and Class 8 cleanrooms, ISO 13485 certified. About $249M revenue
- Relevance
- The direct competitor, and finer-pitch than MERIDIAN's stated 10 micrometers by a factor of three
- Position
- $1,854M revenue in 2025. Cardiac Rhythm Management and Neuromodulation alone $669M
- Relevance
- The scale player, and the margin benchmark
- Position
- Laser micromachining plus thin-film sputtering for high-density flex
- Relevance
- Specialist competitor in the same niche
- Position
- Prints thin-film electrodes by semiconductor-like processes and has commercialized them for epilepsy monitoring
- Relevance
- The closest working analog to what this line would sell, at small scale
The incumbents are not display-supply-chain peers. They are medtech-native thin-film houses that compete on regulatory record and design partnership rather than on cost per square meter.
Three groups, and they matter to different lines.
For the interventional and implantable line:
For the single-use module line, which carries the second-largest share of the plan:
- Position
- Manufactures a wearable electronic-enabled combination drug delivery product for a biotechnology customer; final assembly, test and quality control; over thirteen years of combination product programs
- Relevance
- The incumbent this line competes against directly, and it holds the reference customer relationship
- Position
- Wearable on-body injectors from ISO 13485 sites, on high-precision automation
- Relevance
- Direct competitor with the certificate already held
- Position
- Self-injection platforms including on-body devices, plus contract manufacture
- Relevance
- Often the customer rather than the competitor: MERIDIAN would frequently supply the platform owner rather than the drug owner
- Position
- Named participants in medical device contract manufacturing
- Relevance
- The scale competitors, with electronics capability MERIDIAN would have to beat on cost rather than on capability
For the private-label printed electrode line, which is the largest:
- Position
- Specializes in private-labeling its ECG electrode line for other companies to take to market, manufacturing in the United States and internationally to OEM specification
- Relevance
- The incumbent in exactly this position, and a precedent: Nissha is a printing and film company that entered medical electrodes, which is the same move from the same kind of starting asset
- Position
- More than half the return electrode market under their own brands
- Relevance
- Not addressable. They are the reason merchant share here is 25% rather than higher
And for CGM:
| Competitor | Position | Relevance |
|---|---|---|
| OEM in-house lines | Abbott, Dexcom, Medtronic sensor plants | Not competitors for merchant business. They are the reason there is so little of it |
Two conclusions.
MERIDIAN's fine-pitch capability is not a differentiator where pitch matters. Cirtec publishes 3 micrometers; MERIDIAN states approximately 10. In the two medical applications where pitch is genuinely the binding constraint, electrophysiology mapping catheters and two-dimensional ultrasound arrays, MERIDIAN would be entering behind the incumbent. Everywhere else in medicine the geometry is coarser than MERIDIAN can already do, which means the 10-micrometer capability goes unused and earns no premium.
The genuine advantage is roll-to-roll cost at volume, and it is strongest exactly where those competitors are weakest. Cirtec and MicroConnex are built for low-volume implantable and catheter work. Neither is built for the 891 million printed electrodes a year the private-label line reaches by 2032, which is about ten roll-to-roll lines at a conservative web speed. MERIDIAN has that asset. The right-to-win argument rests on it.
That argument needs one qualification, because elsewhere this analysis says the entry barrier at this stage is regulatory record rather than process capability, and a cost advantage does not clear a barrier made of certificates. It also says that being cheaper than what a buyer does today is the weakest of the three propositions a supplier can offer.
Both hold, and the resolution is that they apply to a different buyer. A private-label distributor does not manufacture at all, so it has no incumbent process to defend and no reason to weigh anything but price, quality record and supply security. Cost is the right proposition for that buyer specifically, which is exactly why merchant share in return electrodes is 25% rather than zero. Against a device maker that already makes the part, the same offer moves nothing, and this analysis does not assume it does.
The barrier and the advantage are therefore sequential rather than competing: the certificate is what gets MERIDIAN into the room, and roll-to-roll cost is what wins the order once it is there. The certificate is also why nothing ships for two years.
One thing has to be said plainly about that advantage, because the largest revenue line rests on it. Nothing in this analysis quantifies MERIDIAN's cost per printed electrode against Nissha's or against any branded manufacturer's. The 22% gross margin used for the private-label line is set from Integer's published margin rather than from a cost position, which means it is what a supplier with no cost advantage would also earn. So the case books two thirds of its 2032 revenue on a share won by an advantage it has not measured, while pricing that revenue as though the advantage did not exist. That is conservative on margin and optimistic on share, and the two do not cancel. Measuring it against a live customer specification is a first-stage test for that reason.
Cirtec at $249M of total revenue is also the scale check. The revenue target would make MERIDIAN's medical business 1.4 times the size of the leading thin-film medical supplier, within three years of entry.
What the industry's own capital is telling us
Where acquirers spend is the clearest available evidence about which value pools are defensible, and it points away from the position under consideration.
Medtech mergers and acquisitions reached about $80B of announced value through 30 November 2025, a decade high. The largest deals were Abbott's planned $21B acquisition of Exact Sciences, Hologic's $18.3B go-private, and Boston Scientific's approximately $14.5B agreement for Penumbra. Strategic acquirers concentrated on cardiovascular, neurostimulation, and connected-device and patient-monitoring platforms.
Every one of those targets owns a regulatory clearance, a clinical franchise and a route to the payer. None of them is a component supplier. No thin-film electrode or flexible-circuit house appears anywhere in the year's significant transactions, and the two largest merchant suppliers in this space are a listed company trading on manufacturing multiples and a private-equity-held business at $249M of revenue.
That is a consistent signal and it says two things. Consolidation is happening at the stage MERIDIAN has ruled out, which is where the defensible pools are. And a component supplier is not a category acquirers compete for, so a successful medical business here would be worth an industrial multiple rather than a medtech one. The terminal value in this analysis is set accordingly.
The corollary is more useful than the warning. If MERIDIAN builds a position at module level and it works, the exit is a trade sale to a contract manufacturer consolidating capability, not a strategic premium from a device maker. That is worth knowing before rather than after.